Black Diamond Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Black Diamond Therapeutics

03/08/2026 14:34

Black Diamond Therapeutics Inc BDTX.OQ BDTX.O is expected to  show no change in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Black Diamond Therapeutics Inc is for a loss of 20 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $9.00, about 432.5% above its last closing price of $1.69
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.18
-0.18
-0.16
Beat
13.4
Dec. 31 2026
-0.23
-0.19
-0.27
Missed
-45
Sep. 30 2025
-0.23
-0.23
-0.15
Beat
36.1​
Jun. 30 2025
-0.25
-0.25
-0.19
Beat
23
​​Mar. 31 2025
0.49
0.02
0.98
Beat
4,511.8
Dec. 31 2024
-0.31
-0.28
Beat
11​
Sep. 30 2024
-0.38
-0.37
-0.28
Beat
25.1
Jun. 30 2024
-0.38
-0.39
-0.36
Beat
7
This summary was machine generated August 3 at 13:34 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)